Reproduction permitted for personal use only. For reprints and reprint permission, contact

Wisconsin court halts Abbott's sale of genotyping products

Madison, Wis. - The U.S. District Court for the Western District of Wisconsin has entered a permanent injunction against Abbott Laboratories, preventing the pharmaceutical company from further sales or use of products or components that infringe on a genotyping patent held by Innogenetics, a biopharmaceutical company based in Gent, Belgium.

The injunction comes after the court upheld a $7 million damage verdict against Abbott. In September of 2006, a Wisconsin jury unanimously found that Abbott had willfully infringed on the patent, which covers a method of genotyping the Hepatitis C Virus, and also awarded damages.

In ruling that the Innogenetics patent was valid, the court overturned the jury's finding that Abbott's infringement had been willful, but also upheld the damage verdict and dismissed Abbott's request for a new trial on infringement.

Innogenetics, which sued Abbott in September of 2005, is considering an appeal on the issue of willfulness.

Related stories
Wisconsin court affirms damages in Innogenetics, Abbott patent case

Michael Rosen: 2006: A mixed blessing for Midwest life science companies

Big pharma seeks Wisconsin biotech partnerships

With patents, Wisconsin court gaining reputation as a "rocket docket"

-Add Your Comment


Comment Policy: WTN News accepts comments that are on-topic and do not contain advertisements, profanity or personal attacks. Comments represent the views of the individuals who post them and do not necessarily represent the views of WTN Media or our partners, advertisers, or sources. Comments are moderated and are not immediately posted. Your email address will not be posted.

WTN Media cannot accept liability for the content of comments posted here or verify their accuracy. If you believe this comment section is being abused, contact

WTN Media Presents